2016, Number 08
<< Back Next >>
Ginecol Obstet Mex 2016; 84 (08)
Breast Cancer Survival: Clinical and Pathological Prognostic Factors Analysis
Maffuz-Aziz A, Labastida- Almendaro S, Sherwell-Cabello S, Ruvalcaba-Limón E, Domínguez-Reyes CA, Tenorio-Torres JA, Rodríguez-Cuevas S
Language: Spanish
References: 19
Page: 498-506
PDF size: 356.58 Kb.
ABSTRACT
Background: Breast cancer is the leading cause of cancer death
in women in Mexico, is a heterogeneous disease, and knowledge of
prognostic factors are critical in making treatment decisions.
Objetive: determine the overall survival (OS) and disease-free
survival (DFS) at 5 years, analyzed by risk groups.
Material and Method: Patients diagnosed with breast treated at
the Institute of Breast Diseases FUCAM from July 2005 to December
2014 were included. Simple frequencies were used for analysis of
the general characteristics, and 5- year OS and DFS were analyzed
using Kaplan-Meier curves. A subset analysis of the clinical stage and
comparing survival in those patients diagnosed by mammography
screening program was performed.
Results: 4,902 patients with breast cancer were included, general
clinical and pathological features are described and 3,762 patients
were included for analysis of 5-year OS and DFS. The average age
at diagnosis was 53.7 years; 13.3% were ‹40 years, which deleteriously
reflects on the supervivencia global 76
vs 84% in›40. At
diagnosis predominated locally advanced stages (45%), OS and DFS
at 5 years was 96.8 ± 0.6% and 93.4%±0.9 respectively for early
stages, 74.6 ± 1.7% and 68.7 ± 2% for locally advanced and 35.9
± 5.1% and 37.4 ± 10.3% for metastatic tumors. Women diagnosed
in the screening program had significantly better OS and DFS compared
with symptomatic patients (95 and 93%
vs 79 and 77%). For
biological subtypes, OS and DFS was 89 and 84% for luminal, 81
and 81% for luminal Her +, 74 and 78% for pure Her 2, and 69 and
73% for triple negative.
Conclusions: Knowledge of the prognostic factors that affect
survival of patients with breast cancer is essential for categorizing
risk groups and to individualize treatment in order to improve life
expectancy.
REFERENCES
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014:136:359-386.
Online Instituto Nacional de Geografía y Estadística. México 2014. Disponible en http://www.inegi.org.mx/inegi/contenidos/ espanol/prensa/Contenidos/estadisticas/2014/ mama0.pdf (consultada el 24 de abril del 2016).
Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, Hernández- Ávila M. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Pública Mex 2009;51(Supl2)s208-s219.
Online International Agency for Research on Cancer, Globocan. World Health Organization 2012. Disponible en http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx, consultado el 24 de abril del 2016.
Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat. 2005;89:47-54.
Goldhirch A, Winer EP, Coates AS, Gelber RD, Piccart- Gebhart M, Thürlimann B, et. al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;29(4):2206-23.
Cárdenas-Sánchez J, Bargallo-Rocha E, Erazo-Valle A, Maafs-Molina E, Poitevin-Chacon A. Epidemiología del cáncer mamario en México. En: Consenso Mexicano de diagnóstico y tratamiento del cáncer mamario. Colima: Mason Doyma, 2013; 5-6.
http://www.salud.df.gob.mx/portal/seguro_popular/ index/gastos.php consultado el 10 de mayo del 2016.
AJCC Cancer Staging Manual, Seventh Edition. Springer 2010;347-376.
Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001;91:863-868.
http://seer.cancer.gov/statfacts/html/breast.html consultado el 1 de mayo del 2016.
http://www.cancerresearchuk.org/health-professional/ cancer-statistics/statistics-by-cancer-type/breast-cancer/ incidence-invasive consultado el 1 de mayo del 2016.
Sherwell-Cabello S. Maffuz-Aziz A, López-Hernández S, Domínguez-Reyes C, Labastida-Almendaro S, Rodríguez- Cuevas S. Young age: The most significant factor contributing to poorer prognosis in Mexican women with breast cancer. J Cancer Biol Res 2015,3(3):1066.
Parise CA, Caggiano V. Breast cancer survival defined by the ER (PR/Her 2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. Journal of Cancer Epidemiology 2014. http:// dx.doi.org/10.1155/2014/469251.
http://www.cancer.org/cancer/breastcancer/detailedguide/ breast-cancer-survival-by-stage (consultado el 28 de abril del 2016).
http://www.cancerresearchuk.org/about-cancer/type/ breast-cancer/treatment/statistics-and-outlook-for-breastcancer# stage (consultado el 28 de abril del 2016).
Perou CM, Sorile T, Einsen MB, et.al. Molecular Portraits of human breast tumours. Nature 2000;406(6797):747- 752.
Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF. Impact of Breast Cancer Subtypes and Treatment on Survival An Analysis Spanning Two Decades. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1848-1855.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539-552.
Full text